PB1806: ULTRA-SENSITIVE MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR LEUKEMIA PATIENTS USING SUPERRCA MUTATION ASSAYS WITH FLOW CYTOMETER READOUT

MLA

Lei Chen, et al. “Pb1806: Ultra-Sensitive Minimal Residual Disease (Mrd) Monitoring for Leukemia Patients Using Superrca Mutation Assays with Flow Cytometer Readout.” HemaSphere, vol. 7, Aug. 2023. EBSCOhost, https://doi.org/10.1097/01.HS9.0000974072.24969.0d.

APA

Lei Chen, Anna Eriksson, Anna Rohlin, Lucia Cavelier, & Ulf Landegren. (2023). Pb1806: Ultra-Sensitive Minimal Residual Disease (Mrd) Monitoring for Leukemia Patients Using Superrca Mutation Assays with Flow Cytometer Readout. HemaSphere, 7. https://doi.org/10.1097/01.HS9.0000974072.24969.0d

Chicago

Lei Chen, Anna Eriksson, Anna Rohlin, Lucia Cavelier, and Ulf Landegren. 2023. “Pb1806: Ultra-Sensitive Minimal Residual Disease (Mrd) Monitoring for Leukemia Patients Using Superrca Mutation Assays with Flow Cytometer Readout.” HemaSphere 7 (August). doi:10.1097/01.HS9.0000974072.24969.0d.